‡Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit or call for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy., Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, giant cell arteritis, and polyarticular juvenile idiopathic arthritis. Information includes Rinvoq side effects, interactions, and indications., Find patient medical information for Rinvoq (upadacitinib) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings.